375 related articles for article (PubMed ID: 37165457)
1. Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.
Segura-Collar B; Hiller-Vallina S; de Dios O; Caamaño-Moreno M; Mondejar-Ruescas L; Sepulveda-Sanchez JM; Gargini R
Acta Neuropathol Commun; 2023 May; 11(1):79. PubMed ID: 37165457
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
4. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C; Yu M; Zhang W
Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
[TBL] [Abstract][Full Text] [Related]
5. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
7. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
8. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
9. Considerations for personalized neoantigen vaccination in Malignant glioma.
Dunn GP; Sherpa N; Manyanga J; Johanns TM
Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
[TBL] [Abstract][Full Text] [Related]
10. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
11. The current and future aspects of glioblastoma: Immunotherapy a new hope?
Patel V; Shah J
Eur J Neurosci; 2021 Aug; 54(3):5120-5142. PubMed ID: 34107127
[TBL] [Abstract][Full Text] [Related]
12. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
14. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
15. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
16. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
17. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
18. Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment.
Dain L; Zhu G
Int J Pharm; 2023 May; 638():122924. PubMed ID: 37037396
[TBL] [Abstract][Full Text] [Related]
19. Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors.
Du Y; Liu Y; Wang D; Bai H; Wang Z; He X; Zhang P; Tian J; Wang J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217574
[TBL] [Abstract][Full Text] [Related]
20. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
